Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection
Study to evaluate the safety and effectiveness of 2.5 mg and 5 mg tadalafil when taken by men with diabetes mellitus who have problems getting and maintaining an erection...
Brief Summary
Official Title: “A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5 mg and 5 mg) Administered Once Daily to Men With Diabetes Mellitus and Erectile Dysfunction”
Study to evaluate the safety and effectiveness of 2.5 mg and 5 mg tadalafil when taken by men with diabetes mellitus who have problems getting and maintaining an erection.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: tadalafil
- 2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
- Drug: tadalafil
- 5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
- Drug: placebo
- Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: 2
- 2.5 mg tadalafil
- Active Comparator: 3
- 5 mg tadalafil
- Placebo Comparator: 1
Outcome Measures for this Clinical Trial
Primary Measures
- Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in the SEP diary
- Time Frame: 12 weeks
- Time Frame: 12 weeks
Secondary Measures
- Change in the GAQ, SEP, IIEF, SEAR, and RSE scores.
- Time Frame: 12 weeks
- Time Frame: 12 weeks
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- History of erectile dysfunction for at least 3 months.
- Currently have diabetes mellitus of at least 3 months duration.
- Agree to not use any other ED treatment during the study.
- Anticipate the same female sexual partner for the study.
- Must be willing to make the required number of sexual attempts.
Exclusion Criteria:
- History of other primary sexual disorder
- Treatment with nitrates or potent CYP3A4 inhibitors
- Have a penile implant or clinically significant penile deformity
- History of certain heart problems
- Have kidney or liver problems
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Eli Lilly and Company Industry
Overall Clinical Trial Officials and Contacts
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) Study Director Eli Lilly and Company
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00547183
Study ID Number: 8702
ClinicalTrials.gov Identifier: NCT00547183
Health Authority: United States: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00547183
